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.A clinical and family history study
of Parkinson’s disease in
heterozygous glucocerebrosidase
mutation carriers
Type I Gaucher disease (GD), the most
common lysosomal storage disorder, is caused
by recessive glucocerebrosidase mutations.1
Both patients with Type I GD and hetero-
zygous glucocerebrosidase mutation carriers
have increased Parkinson’s disease (PD) risk.1
Non-motor symptoms (NMS) are more
frequent in PD with heterozygous glucocer-
ebrosidase mutations (PD-GBA).2 We used
the non-motor symptoms scale (NMSS) and
Parkinson’s disease questionairre (PDQ-39) to
quantify NMS in PD-GBA.3 The age related
PD risk in heterozygous glucocerebrosidase
carriers has been reported in familial PD.4
Here, we calculate PD risk in obligate carrier
relatives (parents) of Type I GD patients.
Patients and methods
PD-GBA patients were identiﬁed by Sanger
sequencing of the glucocerebrosidase gene in
220 sporadic PD (PD-S) patients. The G2019S
mutation in LRRK2 had previously been
excluded. A control group of glucocere-
brosidase mutation negative PD-S were
selected from the same cohort. Each partici-
pant had the following administered: 40 item
smell identiﬁcation test (SIT), Montreal
Cognitive assessment (MoCA), Parts IeIV of
Uniﬁed Parkinson’s Disease Rating Scale
(UPDRS), NMSS, PDQ-39 and Rapid Eye
Movement (REM) Sleep Behaviour Disorder
Questionnaire (RBDQ). Statistical analysis
was performed using SPSS (version 17). The
proportion of participants with a MoCA score
<26/30 (signifying mild cognitive impair-
ment) or RBDQ >6/10 (signifying possible
REM sleep behaviour disorder) was compared
using the c2 test.3 In parallel, family history
data were obtained from 83 Type I GD
patients, detailing age of onset of PD in their
parents (n¼166, who are obligate carriers).
Age related risk of PD was calculated with
KaplaneMeier analysis. Parents with PDwere
also enrolled into the phenotyping study.
RESULTS
Of 220 PD patients sequenced, 12 (5.5%) had
a heterozygous glucocerebrosidase mutation,
and nine were available for follow-up. Three
parents of GD patients with PD were
recruited, giving a cohort of 12 PD-GBA
patients (5/12 female subjects, mean age 65
(range 49e81 years), 1/12 (8%) Ashkenazi
Jewish mean disease duration 8 years (range
2e15)). Twenty out of 208 PD patients
without glucocerebrosidase mutations (7/20
female subjects, mean age 65 (range
50e83 years), 2/20 Ashkenazi (10%) disease
duration 9 years (range 2e20 years)) were
selected as controls matched for age, sex and
disease duration. Mutations in the PD-GBA
group who underwent clinical phenotyping
were: N370S (5/12, 42%), L444P (2/12, 16%),
recombinant alleles (2/12, 16%), R496H (1/
12, 8.3%), V460L (1/12, 8.3%) and IVS2+1
(1/12, 8.3%). The groups were matched for
use of levo-dopa (75% vs 60%, p¼0.067) and
UPDRS parts I (PD-GBA median 8 vs PD-S 9,
p¼0.95), II (17 vs 18, p¼0.067), III (33 vs 34,
p¼0.13) and IV scores (1 vs 0, p¼0.13). No
patient had deep brain stimulation but two
PD-GBA patients were on selective serotonin
reuptake inhibitors for depression. All PD-
GBA and PD-S had olfactory dysfunction on
the SIT with no difference between group
medians (16/40 vs 15, p¼0.503). Using a cut-
off score of 26/30 on the MoCA, signiﬁcantly
more PD-GBA had cognitive impairment
than PD-S (7/12 (58%) vs 5/20 (25%),
p¼0.014). PD-GBA scores for abstraction
(mean 1.4 vs 2, p¼0.023) and orientation
(mean 5 vs 5.8, p¼0.016) were signiﬁcantly
lower, and there was a trend for PD-GBA
attention scores to be lower (mean 4.8 vs 5.5,
p¼0.055). The overall NMSS score was
higher for PD-GBA than PD-S (median 104
(IQR 69e134) vs 38 (16e60), p¼0.002). PD-
GBA reported more symptoms per partici-
pant than PD-S (median 13 (range 1e19) vs
median 7 (range 1e14), p¼0.0012). The
following were more common in PD-GBA:
falls with loss of consciousness (25% vs 0%,
p¼0.04), fatigue (92% vs 30%, p¼0.001),
unexplained pain (58% vs 10%, p¼0.005),
loss of interest in life (66% vs 5%, p¼0.0004),
anxiety (66% vs 20%, p¼0.02) and apathy
(50% vs 10%, p¼0.03). PDQ-39 summary
index scores were worse in PD-GBA than
PD-S (mean 37 (SD 25) vs mean 21 (SD 13),
p¼0.032). Subsections in which PD-GBA
Figure 1 KaplaneMeier analysis of age related risk of developing Parkinson’s disease. Risk is
derived from family history data on 166 obligate carriers of glucocerebrosidase mutations (parents
of Type I Gaucher disease patients), combined for men and women. Overall lifetime RR of
Parkinson’s disease was 30 (95% CI 7 to 122) in carriers compared to the London population.
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had worse scores were emotion (mean 12.5
vs 3.3, p¼0.008) and discomfort (mean 21.5
vs mean 6.3, p¼0.01) with cognition (mean
25 vs mean 12.5, p¼0.075) and ADL (mean
38.4 vs 21, p¼0.052) being non-signiﬁcantly
worse. Using a cut-off score of 6/10, more
PD-GBA participants screened positive for
REM sleep disorder than PD-S (7/12 (58%)
vs 1/20 (5%), p¼0.0016).
Data on 166 parents of Type I GD patients
were available (17/83 (20%) families Ashke-
nazi Jewish, 5/83 (6%) Eastern European and
the remainder Caucasian UK citizens, no
consanguineous families). A PD case was
deﬁned by the proband reporting a deﬁnite
medical diagnosis in their parents. Ten cases of
PD were identiﬁed, and three were examined
in person to conﬁrm diagnosis (these are
included in the cohort of 12 PD-GBA
described above). Of the 10 cases of PD in
relatives, ﬁve were male subjects (50%) and
mean age of onset was 67 (SD 8.6 years).
Figure 1 shows a KaplaneMeier analysis for
developing PD for men and women combined.
Age related risk of PD peaked at age 80 (15%).
Based on the London population,5 0.33 cases
of PD would be expected in our cohort of 166
(derived from lifetime prevalence of 2/1000 for
men and women). This gave a lifetime RR of
30 (95% CI 7 to 122).
DISCUSSION
Here, we conﬁrm reports of more severe
cognitive dysfunction, depression and
anxiety in PD-GBA.2 Using the NMSS and
PDQ-39, we demonstrate for the ﬁrst time
a greater burden of NMS, with lower quality
of life in PD-GBA. The number of NMS per
patient and severity of symptoms were
signiﬁcantly higher, even though both
groups were at a similar stage and duration
of PD. Interestingly, a positive result on the
RBD screening questionnaire was signiﬁ-
cantly more common in PD-GBA, suggesting
REM sleep behaviour disorder may be more
prevalent in PD-GBA. This needs conﬁrma-
tion with sleep studies. The midbrain raphe
is involved in sleep regulation and is more
frequently abnormal on transcranial sonog-
raphy in PD-GBA than PD-S.2 This may
explain the apparently increased REM sleep
behaviour disorder in PD-GBA. Olfactory
dysfunction in PD-GBA and PD-S was
equivalent. This contrasts with LRRK2 and
Parkin mutation associated PD in which
olfactory dysfunction is less severe than in
PD-S.3 This suggests that the pathological
process in PD-GBA and PD-S involves
olfactory pathways to a similar extent. The
more severe cognitive dysfunction in PD-
GBA implies that there may be more wide-
spread cortical pathology than in PD-S. Our
clinical ﬁndings of more severe NMS corre-
late with pathological studies indicating that
PD-GBA may be associated with more
widespread Lewy body pathology.1
Lifetime RR of PD in our cohort of 166
obligate carriers was 30, with a cumulative
risk of 5% at age 60 rising to 15% at age 80.
This risk is similar to that for Type I GD
patients.1 The risk in our cohort is less than
the 13.7% (age 60) and 29.7% (age 80)
reported in familial PD-GBA.4 It may be that
additional genetic or environmental factors
in these PD-GBA families are contributing to
an increased risk compared with our GD
families. Taken together, these studies
conﬁrm a high, age related risk of PD in
heterozygous carriers which may differ with
ethnic group and family history of GD. This
will help to inform genetic counselling of
parents of patients with Type I GD.
Alisdair McNeill,1 Raquel Duran,2
Derralynn A Hughes,3 Atul Mehta,3
Anthony H V Schapira1
1Department of Clinical Neurosciences, Institute of
Neurology, UCL Medical School, London, UK;
2Department of Molecular Neuroscience, Institute of
Neurology, London, UK; 3Lysosomal Storage Disorders
Unit, Royal Free Hospital, London, UK
Correspondence to Professor Anthony H V Schapira,
Department of Clinical Neurosciences, Rowland Hill St.,
London NW3 2PF, UK; a.schapira@ucl.ac.uk
Contributors Author roles 1. Research project: A.
Conception, B. Organisation, C. Execution; 2. Statistical
analysis: A. Design, B. Execution, C. Review and critique;
3. Manuscript preparation: A. Writing of the first draft, B.
Review and critique. Alisdair McNeill: 1A, 1B, 1C, 2A,
2B, 3A; Raquel Duran: 1C, 2C, 3B; Anthony Schapira:
1A, 2C, 3B; D Hughes: 1B, 2C, 3B: A Mehta: 1B, 2C, 3B.
Funding This work was supported by the United
Kingdom Medical Research Council (MRC Clinical
Research Training Fellowship to AM, MRC Award
G1001983) and the Wellcome Trust/MRC Joint Call in
Neurodegeneration Award (WT089698). Alisdair McNeill
is supported by the UK Medical Research Council (MRC).
Anthony Schapira is supported by the MRC, Wellcome
Trust, the UK Parkinson’s disease society (PDUK) and
the Kattan Trust. Dr Raquel Duran received a fellowship
from Fundacion Martin Escudero. Dr Derralyn Hughes
has received research grants, honoraria for speaking and
advisory boards from Genzyme, Shire and Actilion.
Professor Atul Mehta has received research grants,
honoraria for speaking and advisory boards from
Genzyme, Shire and Actilion.
Competing interests None.
Ethics approval Ethics approval was approved by the
North West London REC.
Provenance and peer review Not commissioned;
externally peer reviewed.
Received 30 January 2012
Revised 12 March 2012
Accepted 29 March 2012
Published Online First 10 May 2012
J Neurol Neurosurg Psychiatry 2012;83:853e854.
doi:10.1136/jnnp-2012-302402
REFERENCES
1. Westbroek W, Gustafson AM, Sidransky E. Exploring
the link between glucocerebrosidase mutations
and Parkinsonism. Trends Mol Med 2011;17:
485e93.
2. Brockmann K, Srulijes K, Hauser AK, et al. GBA
associated PD presents with non-motor
characteristics. Neurology 2011;77:276e80.
3. Chauduri KR, Healy DG, Schapira AH. Non-motor
symptoms of Parkinson’s disease: diagnosis and
management. Lancet Neurol 2006;5:235e45.
4. Anheim M, Elbaz A, Lesage S, et al. Penetrance of
Parkinson disease in glucocerebrosidase gene mutation
carriers. Neurology 2012;78:417e20.
5. McDonald BK, Cockerell OC, Sander JW, et al. The
incidence and lifetime prevalence of neurological
disorders in a prospective community based study in
the UK. Brain 2000;123:665e76.
854 J Neurol Neurosurg Psychiatry August 2012 Vol 83 No 8
PostScript
Open Access This is an Open Access article
distributed in accordance with the Creative Commons
Attribution Non Commercial (CC BY-NC 3.0) license,
which permits others to distribute, remix, adapt, build
upon this work non-commercially, and license their
derivative works on different terms, provided the original
work is properly cited and the use is non-commercial.
See: http://creativecommons.org/licenses/by-nc/3.0/
 group.bmj.com on June 17, 2013 - Published by jnnp.bmj.comDownloaded from 
doi: 10.1136/jnnp-2012-302402
online May 10, 2012
 2012 83: 853-854 originally publishedJ Neurol Neurosurg Psychiatry
 
Alisdair McNeill, Raquel Duran, Derralynn A Hughes, et al.
 
glucocerebrosidase mutation carriers
Parkinson's disease in heterozygous 
A clinical and family history study of
 http://jnnp.bmj.com/content/83/8/853.full.html
Updated information and services can be found at: 
These include:
References
 http://jnnp.bmj.com/content/83/8/853.full.html#related-urls
Article cited in: 
 
 http://jnnp.bmj.com/content/83/8/853.full.html#ref-list-1
This article cites 5 articles, 3 of which can be accessed free at:
Open Access
http://creativecommons.org/licenses/by-nc/3.0/legalcode
http://creativecommons.org/licenses/by-nc/3.0/ and 
compliance with the license. See:
work is properly cited, the use is non commercial and is otherwise in 
use, distribution, and reproduction in any medium, provided the original
Creative Commons Attribution Non-commercial License, which permits 
This is an open-access article distributed under the terms of the
service
Email alerting
the box at the top right corner of the online article.
Receive free email alerts when new articles cite this article. Sign up in
Collections
Topic
 (63 articles)Open access   
 
Articles on similar topics can be found in the following collections
Notes
 http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
 http://journals.bmj.com/cgi/reprintform
To order reprints go to:
 http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
 group.bmj.com on June 17, 2013 - Published by jnnp.bmj.comDownloaded from 
